(Q34280051)

1 August 2017

title

Side effects of anti-angiogenic drugs (English)

1 reference

1 August 2017

main subject

angiogenesis inhibitor

1 reference

2

Francesco Rodeghiero

1 reference

1 August 2017

Francesca Elice

1

1 reference

1 August 2017

publication date

1 April 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

129 Suppl 1

1 reference

1 August 2017

page(s)

S50-3

1 reference

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Thrombosis associated with angiogenesis inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970016-6

7 January 2021

10.1016/S0049-3848(12)70016-6

Identifiers

DOI

1 reference

1 August 2017

1 reference